- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Contineum Therapeutics Inc (CTNM)
Contineum Therapeutics Inc stock price live, this page displays NASDAQ CTNM stock exchange data. View the CTNM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Contineum Therapeutics Inc real time stock price chart below.
What Is the Contineum Therapeutics Inc Stock Price Today?
The Contineum Therapeutics Inc stock price today is 6.47.
What Is the Stock Symbol for Contineum Therapeutics Inc?
The stock symbol for Contineum Therapeutics Inc is ""CTNM.""
What Stock Exchange Does Contineum Therapeutics Inc Trade On?
Contineum Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Contineum Therapeutics Inc a Good Stock to Buy?
Determining whether Contineum Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTNM quote. (ISIN: US21217B1008)
What Is the Contineum Therapeutics Inc Stock Price Today?
The Contineum Therapeutics Inc stock price today is 6.47.
What Is the Stock Symbol for Contineum Therapeutics Inc?
The stock symbol for Contineum Therapeutics Inc is ""CTNM.""
What Stock Exchange Does Contineum Therapeutics Inc Trade On?
Contineum Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Contineum Therapeutics Inc a Good Stock to Buy?
Determining whether Contineum Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTNM quote. (ISIN: US21217B1008)
NASDAQ
Currency in USD
6.47
-0.26(-3.86%)
Closed·
After Hours
6.470.00(0.00%)
·
Fair Value
An estimate of a Contineum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.25
6.80
52 wk Range
3.35
20.55
CTNM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CTNM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Contineum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.256.80
52 wk Range
3.3520.55
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CTNM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Contineum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
22.71
Upside
+251.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K Contineum Therapeutics Inc For: 26 June
- Investing.com
- Form 8K Contineum Therapeutics Inc For: 26 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Contineum Therapeutics Inc Company Profile
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Contineum Therapeutics Inc SWOT Analysis
Promising Pipeline | Explore Contineum's key assets '791 and '307, targeting high-need markets like IPF, MS, and depression, with potential for expanded indications |
Clinical Milestones | Anticipate crucial PET receptor occupancy data for '791 in H1 2025, potentially de-risking development for IPF and progressive MS indications |
Market Opportunities | Delve into Contineum's strategy to address substantial patient populations in IPF, MS, and depression, leveraging its innovative compounds |
Financial Outlook | Analysts maintain "Outperform" rating with price targets ranging from $25 to $32, reflecting confidence in Contineum's long-term prospects |
Compare CTNM to Peers and Sector
Metrics to compare | CTNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.9x | −0.4x | −0.5x | |
PEG Ratio | −0.20 | 0.02 | 0.00 | |
Price/Book | 1.0x | 2.0x | 2.6x | |
Price / LTM Sales | - | 1.5x | 3.3x | |
Upside (Analyst Target) | 243.7% | 230.5% | 43.4% | |
Fair Value Upside | Unlock | 6.3% | 7.1% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 22.71
(+251.00% Upside)
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
-0.62 / -0.28
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Contineum Therapeutics Trade On?
Contineum Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Contineum Therapeutics?
The stock symbol for Contineum Therapeutics is "CTNM."
What Is the Contineum Therapeutics Market Cap?
As of today, Contineum Therapeutics market cap is 174.12M.
What Is Contineum Therapeutics's Earnings Per Share (TTM)?
The Contineum Therapeutics EPS (TTM) is -2.20.
When Is the Next Contineum Therapeutics Earnings Date?
Contineum Therapeutics will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is CTNM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Contineum Therapeutics Stock Split?
Contineum Therapeutics has split 0 times.
How Many Employees Does Contineum Therapeutics Have?
Contineum Therapeutics has 41 employees.
What is the current trading status of Contineum Therapeutics (CTNM)?
As of 08 Aug 2025, Contineum Therapeutics (CTNM) is trading at a price of 6.47, with a previous close of 6.73. The stock has fluctuated within a day range of 6.25 to 6.80, while its 52-week range spans from 3.35 to 20.55.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.